NOVACYT (ALNOV.PA)
FR0010397232 - Common Stock
Taking everything into account, ALNOV scores 2 out of 10 in our fundamental rating. ALNOV was compared to 73 industry peers in the Biotechnology industry. The financial health of ALNOV is average, but there are quite some concerns on its profitability. ALNOV is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ALNOV had negative earnings in the past year.
In the past year ALNOV has reported a negative cash flow from operations.
In the past 5 years ALNOV reported 4 times negative net income.
In multiple years ALNOV reported negative operating cash flow during the last 5 years.
1.2 Ratios
ALNOV has a Return On Assets (-21.14%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -32.43%, ALNOV is in the better half of the industry, outperforming 60.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.14% | ||
| ROE | -32.43% | ||
| ROIC | N/A |
ROA(3y)-14.9%
ROA(5y)-1.97%
ROE(3y)-20.54%
ROE(5y)-3.98%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALNOV has a Gross Margin (32.21%) which is in line with its industry peers.
ALNOV's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ALNOV so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.21% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24.98%
GM growth 5Y-12.34%
2. Health
2.1 Basic Checks
ALNOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALNOV remains at a similar level compared to 1 year ago.
Compared to 5 years ago, ALNOV has more shares outstanding
Compared to 1 year ago, ALNOV has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.82, we must say that ALNOV is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.82, ALNOV is in line with its industry, outperforming 57.35% of the companies in the same industry.
ALNOV has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
ALNOV has a better Debt to Equity ratio (0.15) than 67.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.82 |
ROIC/WACCN/A
WACC8.18%
2.3 Liquidity
A Current Ratio of 2.92 indicates that ALNOV has no problem at all paying its short term obligations.
ALNOV has a Current ratio of 2.92. This is in the better half of the industry: ALNOV outperforms 64.71% of its industry peers.
A Quick Ratio of 2.82 indicates that ALNOV has no problem at all paying its short term obligations.
ALNOV has a better Quick ratio (2.82) than 64.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.92 | ||
| Quick Ratio | 2.82 |
3. Growth
3.1 Past
ALNOV shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.45%.
Looking at the last year, ALNOV shows a very negative growth in Revenue. The Revenue has decreased by -44.97% in the last year.
Measured over the past years, ALNOV shows a decrease in Revenue. The Revenue has been decreasing by -1.03% on average per year.
EPS 1Y (TTM)-8.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.59%
Revenue 1Y (TTM)-44.97%
Revenue growth 3Y-65.3%
Revenue growth 5Y-1.03%
Sales Q2Q%81.82%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y8.21%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year48.47%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ALNOV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 2.99, the valuation of ALNOV can be described as very cheap.
91.18% of the companies in the same industry are more expensive than ALNOV, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.99, ALNOV is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 2.99 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ALNOV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NOVACYT
EPA:ALNOV (9/13/2024, 7:00:00 PM)
0.797
-0.03 (-3.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap56.29M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 2.99 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.14% | ||
| ROE | -32.43% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.21% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.92 | ||
| Quick Ratio | 2.82 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-8.45%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y8.21%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-44.97%
Revenue growth 3Y-65.3%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y